As we look toward 2034, the India Diabetes Market is poised to become one of the most significant segments in the global healthcare economy. The sheer volume of patients in India necessitates a robust and scalable approach to treatment. Pharmaceutical innovators are increasingly looking at fixed-dose combinations and long-acting insulin analogues to enhance patient convenience and therapy...